Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 8 | 2025 | 348 | 2.630 |
Why?
|
| Premature Birth | 3 | 2023 | 141 | 1.540 |
Why?
|
| Biosensing Techniques | 2 | 2022 | 4 | 1.440 |
Why?
|
| MicroRNAs | 2 | 2022 | 16 | 1.430 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 45 | 1.280 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 22 | 1.270 |
Why?
|
| Pregnancy | 17 | 2025 | 1535 | 1.260 |
Why?
|
| Life Style | 3 | 2021 | 332 | 1.250 |
Why?
|
| Blood Glucose | 4 | 2022 | 348 | 1.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 755 | 0.990 |
Why?
|
| Ethnic Groups | 2 | 2019 | 474 | 0.950 |
Why?
|
| Humans | 32 | 2025 | 17707 | 0.950 |
Why?
|
| Food Assistance | 1 | 2025 | 9 | 0.940 |
Why?
|
| Female | 27 | 2025 | 12729 | 0.920 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2024 | 3 | 0.910 |
Why?
|
| Signal Transduction | 2 | 2021 | 30 | 0.850 |
Why?
|
| Triclosan | 1 | 2022 | 4 | 0.820 |
Why?
|
| Pediatric Obesity | 2 | 2024 | 85 | 0.820 |
Why?
|
| Pregnancy Complications | 2 | 2025 | 203 | 0.810 |
Why?
|
| Prenatal Care | 2 | 2021 | 129 | 0.790 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 36 | 0.790 |
Why?
|
| Adult | 17 | 2025 | 7658 | 0.780 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 483 | 0.760 |
Why?
|
| Preconception Care | 1 | 2021 | 44 | 0.720 |
Why?
|
| Prospective Studies | 7 | 2025 | 1287 | 0.700 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 2 | 0.680 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 2 | 0.680 |
Why?
|
| NF-kappa B | 1 | 2020 | 11 | 0.680 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 5 | 0.680 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2020 | 1 | 0.680 |
Why?
|
| Eicosanoids | 1 | 2020 | 1 | 0.680 |
Why?
|
| Sirtuin 1 | 1 | 2020 | 1 | 0.680 |
Why?
|
| Reperfusion Injury | 1 | 2020 | 2 | 0.680 |
Why?
|
| Thinness | 1 | 2020 | 32 | 0.670 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2020 | 8 | 0.670 |
Why?
|
| Olmesartan Medoxomil | 1 | 2019 | 1 | 0.670 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 10 | 0.660 |
Why?
|
| Cohort Studies | 7 | 2025 | 2589 | 0.660 |
Why?
|
| Phospholipids | 1 | 2019 | 3 | 0.660 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2019 | 3 | 0.660 |
Why?
|
| Nutritional Status | 1 | 2019 | 31 | 0.650 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2019 | 11 | 0.650 |
Why?
|
| Diabetic Nephropathies | 1 | 2019 | 26 | 0.650 |
Why?
|
| Platinum | 1 | 2019 | 1 | 0.650 |
Why?
|
| Metal Nanoparticles | 1 | 2019 | 1 | 0.650 |
Why?
|
| Immobilized Nucleic Acids | 1 | 2019 | 1 | 0.650 |
Why?
|
| DNA Probes | 1 | 2019 | 2 | 0.650 |
Why?
|
| Cardiovascular System | 1 | 2018 | 4 | 0.620 |
Why?
|
| Healthy Aging | 1 | 2018 | 8 | 0.610 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 717 | 0.610 |
Why?
|
| Health Status Disparities | 1 | 2019 | 147 | 0.580 |
Why?
|
| Young Adult | 7 | 2025 | 2450 | 0.560 |
Why?
|
| Fetal Macrosomia | 1 | 2017 | 27 | 0.550 |
Why?
|
| Male | 15 | 2024 | 10094 | 0.540 |
Why?
|
| Attitude to Health | 1 | 2017 | 159 | 0.510 |
Why?
|
| Animals | 4 | 2020 | 262 | 0.500 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 215 | 0.460 |
Why?
|
| Maternal Exposure | 2 | 2025 | 62 | 0.450 |
Why?
|
| Infant, Newborn | 4 | 2025 | 857 | 0.450 |
Why?
|
| Pregnancy Outcome | 3 | 2025 | 162 | 0.430 |
Why?
|
| Self Report | 2 | 2018 | 252 | 0.400 |
Why?
|
| Case-Control Studies | 4 | 2025 | 1117 | 0.390 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2024 | 167 | 0.380 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2022 | 2 | 0.360 |
Why?
|
| Electrochemical Techniques | 2 | 2022 | 2 | 0.360 |
Why?
|
| Limit of Detection | 2 | 2022 | 2 | 0.360 |
Why?
|
| Mice | 2 | 2020 | 69 | 0.330 |
Why?
|
| Creatinine | 2 | 2020 | 65 | 0.330 |
Why?
|
| Communication | 2 | 2020 | 191 | 0.310 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 212 | 0.300 |
Why?
|
| Risk Factors | 4 | 2023 | 3367 | 0.290 |
Why?
|
| Environmental Pollutants | 2 | 2025 | 48 | 0.280 |
Why?
|
| Patient Participation | 1 | 2018 | 132 | 0.280 |
Why?
|
| Self Care | 1 | 2018 | 164 | 0.280 |
Why?
|
| Aged | 6 | 2022 | 6150 | 0.280 |
Why?
|
| Body Mass Index | 3 | 2020 | 970 | 0.270 |
Why?
|
| Child | 5 | 2024 | 2481 | 0.260 |
Why?
|
| Middle Aged | 7 | 2021 | 7976 | 0.260 |
Why?
|
| Obesity | 2 | 2018 | 841 | 0.260 |
Why?
|
| Prevalence | 3 | 2020 | 882 | 0.260 |
Why?
|
| Medical Informatics | 1 | 2016 | 37 | 0.260 |
Why?
|
| Bayes Theorem | 2 | 2023 | 72 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 381 | 0.250 |
Why?
|
| Urban Population | 1 | 2016 | 114 | 0.250 |
Why?
|
| Parabens | 1 | 2025 | 4 | 0.240 |
Why?
|
| Poverty | 1 | 2016 | 166 | 0.240 |
Why?
|
| Child, Preschool | 4 | 2024 | 1417 | 0.240 |
Why?
|
| Organophosphates | 1 | 2024 | 9 | 0.230 |
Why?
|
| Flame Retardants | 1 | 2024 | 11 | 0.230 |
Why?
|
| United States | 3 | 2024 | 3914 | 0.230 |
Why?
|
| Child Development | 1 | 2024 | 53 | 0.220 |
Why?
|
| Hispanic Americans | 1 | 2016 | 397 | 0.220 |
Why?
|
| Cesarean Section | 1 | 2024 | 33 | 0.220 |
Why?
|
| Adolescent | 3 | 2021 | 3671 | 0.210 |
Why?
|
| Eclampsia | 1 | 2023 | 12 | 0.210 |
Why?
|
| Fluorocarbons | 1 | 2023 | 13 | 0.210 |
Why?
|
| African Americans | 1 | 2016 | 465 | 0.210 |
Why?
|
| Phenol | 1 | 2022 | 4 | 0.210 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 44 | 0.200 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 3 | 0.200 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 23 | 0.200 |
Why?
|
| Endonucleases | 1 | 2022 | 3 | 0.200 |
Why?
|
| Electronic Health Records | 2 | 2018 | 694 | 0.200 |
Why?
|
| California | 2 | 2025 | 2327 | 0.200 |
Why?
|
| DNA | 1 | 2022 | 22 | 0.200 |
Why?
|
| Phenols | 1 | 2022 | 34 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2020 | 9 | 0.190 |
Why?
|
| Rats | 2 | 2020 | 30 | 0.190 |
Why?
|
| Autistic Disorder | 1 | 2023 | 100 | 0.190 |
Why?
|
| Kidney | 2 | 2020 | 53 | 0.190 |
Why?
|
| Glycolysis | 1 | 2021 | 1 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 3 | 0.180 |
Why?
|
| Up-Regulation | 1 | 2021 | 7 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 15 | 0.180 |
Why?
|
| Hypoxia | 1 | 2021 | 8 | 0.180 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 371 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 51 | 0.180 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 165 | 0.170 |
Why?
|
| Pandemics | 4 | 2023 | 286 | 0.170 |
Why?
|
| Apoptosis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 19 | 0.170 |
Why?
|
| Blood Urea Nitrogen | 1 | 2020 | 8 | 0.170 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 3 | 0.170 |
Why?
|
| Albuminuria | 1 | 2019 | 38 | 0.160 |
Why?
|
| Inverted Repeat Sequences | 1 | 2019 | 1 | 0.160 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 2 | 0.160 |
Why?
|
| Calibration | 1 | 2019 | 8 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 125 | 0.160 |
Why?
|
| Feedback | 1 | 2019 | 19 | 0.160 |
Why?
|
| Qualitative Research | 2 | 2021 | 257 | 0.160 |
Why?
|
| Gestational Age | 1 | 2019 | 116 | 0.160 |
Why?
|
| Consumer Behavior | 1 | 2019 | 27 | 0.160 |
Why?
|
| Minority Groups | 1 | 2019 | 101 | 0.160 |
Why?
|
| Text Messaging | 1 | 2019 | 29 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2019 | 137 | 0.150 |
Why?
|
| Prediabetic State | 1 | 2019 | 56 | 0.150 |
Why?
|
| Disease Progression | 1 | 2019 | 266 | 0.150 |
Why?
|
| Insulin | 1 | 2019 | 213 | 0.150 |
Why?
|
| Biomarkers | 1 | 2019 | 312 | 0.150 |
Why?
|
| Motivation | 1 | 2019 | 130 | 0.150 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 397 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2018 | 28 | 0.150 |
Why?
|
| Oral Health | 1 | 2018 | 22 | 0.140 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 52 | 0.140 |
Why?
|
| Maternal Behavior | 1 | 2017 | 13 | 0.140 |
Why?
|
| Overweight | 1 | 2019 | 270 | 0.140 |
Why?
|
| Heart Failure | 1 | 2022 | 398 | 0.140 |
Why?
|
| Social Environment | 1 | 2017 | 87 | 0.130 |
Why?
|
| Weight Gain | 1 | 2018 | 175 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 211 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2019 | 1106 | 0.120 |
Why?
|
| Infant | 3 | 2024 | 1199 | 0.120 |
Why?
|
| Depression | 3 | 2023 | 504 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1322 | 0.100 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Lipocalins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Nephritis, Interstitial | 1 | 2012 | 3 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 32 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2018 | 756 | 0.100 |
Why?
|
| Anxiety | 2 | 2022 | 152 | 0.090 |
Why?
|
| Disclosure | 1 | 2021 | 17 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2022 | 140 | 0.090 |
Why?
|
| Focus Groups | 1 | 2021 | 146 | 0.090 |
Why?
|
| Age of Onset | 1 | 2020 | 78 | 0.080 |
Why?
|
| Patient Portals | 1 | 2020 | 24 | 0.080 |
Why?
|
| Metformin | 1 | 2020 | 58 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2020 | 113 | 0.080 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 16 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 185 | 0.080 |
Why?
|
| Registries | 1 | 2020 | 470 | 0.070 |
Why?
|
| Postpartum Period | 2 | 2018 | 99 | 0.070 |
Why?
|
| Chicago | 1 | 2016 | 25 | 0.070 |
Why?
|
| Health Resources | 1 | 2016 | 36 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2018 | 245 | 0.060 |
Why?
|
| Esters | 1 | 2024 | 5 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2024 | 58 | 0.060 |
Why?
|
| Comorbidity | 1 | 2016 | 590 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2016 | 248 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2023 | 34 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 29 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 18 | 0.050 |
Why?
|
| Diet | 1 | 2024 | 367 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 52 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 1322 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 79 | 0.050 |
Why?
|
| Hypertension | 1 | 2016 | 498 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2022 | 101 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 90 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 8 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2021 | 19 | 0.050 |
Why?
|
| Glucose | 1 | 2021 | 32 | 0.050 |
Why?
|
| Mental Health | 1 | 2022 | 161 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 416 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 613 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 222 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 33 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 90 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 108 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 113 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2018 | 223 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 304 | 0.030 |
Why?
|
| Medicaid | 1 | 2018 | 188 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 305 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Fibrosis | 1 | 2012 | 7 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 27 | 0.030 |
Why?
|
Concepts
(209)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->